Revolution Medicines (RVMD) had its Relative Strength (RS) Rating upgraded from 70 to 73 Wednesday — a welcome improvement, but still short of the 80 or higher score you prefer to see.
X
{“@context”:”https://schema.org”,”@type”:”VideoObject”,”name”:”Find The Best Long-Term Investments With IBD Long-Term Leaders”,”description”:”Looking for stocks with solid earnings stablility and a proven track record of outperfomrance across multiple market cycles? Start with IBD Long-Term Leaders.”,”thumbnailUrl”:”https://www.investors.com/wp-content/uploads/2020/04/ZSMf2S8I-640×360.jpg”,”contentUrl”:”https://content.jwplatform.com/manifests/ZSMf2S8I.m3u8″,”uploadDate”:”2020-04-24T09:52:32+0000″,”duration”:”PT69.59S”,”author”:”Matt Galgani”,”publisher”:{“@type”:”Organization”,”name”:”Investor’s Business Daily”,”logo”:{“@type”:”ImageObject”,”url”:”https://www.investors.com/wp-content/uploads/2020/06/ibd-logo.png”},”url”:”https://www.investors.com”},”keywords”:””} As you try to find the best stocks to buy and watch, keep a close on eye on relative price strength.
IBD’s proprietary RS Rating tracks technical performance by showing how a stock’s price action over the last 52 weeks measures up against that of the other stocks in our database.
Decades of market research reveals that the best-performing stocks typically have an 80 or better RS Rating as they launch their biggest price moves. See if Revolution Medicines can continue to rebound and hit that benchmark.
Looking For Winning Stocks? Try This Simple Routine
Revolution Medicines is trying to complete a consolidation with a 56.28 buy point. See if the stock can clear the breakout price in heavy trading.
Revolution Medicines reported negative growth for both sales and earnings last quarter.
The company earns the No. 187 rank among its peers in the Medical-Biomed/Biotech industry group. Ligand Pharmaceuticals (LGND) and Cara Therapeutics (CARA) are also among the group’s highest-rated stocks.
YOU MIGHT ALSO LIKE:
Biotech And Pharmaceutical Industry And Stock News
Which Stocks Are Showing Rising Relative Strength?
Why Should You Use IBD’s Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Identify Bases And Buy Points With Pattern Recognition From MarketSmith
The post Revolution Medicines Sees IBD RS Rating Improve To 73 appeared first on Investor's Business Daily.
————————
Originally published at https://www.investors.com/ibd-data-stories/revolution-medicines-sees-ibd-rs-rating-improve-to-73/ on .
